Comparing Agamree vs Emflaza
| Agamree (vamorolone) | Emflaza (deflazacort) |
|
|---|
| Agamree (vamorolone) | Emflaza (deflazacort) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Duchenne Muscular Dystrophy. Agamree may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Duchenne Muscular Dystrophy. Emflaza may also be used for purposes not listed in this medication guide. |
Related suggestions Duchenne Muscular Dystrophy
|
|||||||||||||||
| More about Agamree (vamorolone) | More about Emflaza (deflazacort) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Agamree side effects |
View all Emflaza side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Agamree prices |
View all Emflaza prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
Other deflazacort brands include: Jaythari | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
2 hours |
N/A |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 577 drugs are known to interact with Agamree:
|
A total of 579 drugs are known to interact with Emflaza:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
October 26, 2023 |
February 09, 2017 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
|||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Duvyzat
Duvyzat (givinostat) is used to treat Duchenne muscular dystrophy (DMD) to delay symptoms and ...
Emflaza
Emflaza (deflazacort) is a corticosteroid medication used to treat a rare genetic disorder called ...
Viltepso
Viltepso (viltolarsen) is used for the treatment of Duchenne muscular dystrophy (DMD) treatable ...
Amondys 45
Amondys 45 (casimersen) is used to treat Duchenne muscular dystrophy (DMD) with a genetic mutation ...
Elevidys
Elevidys is a gene therapy for Duchenne muscular dystrophy, that is given as a one-time infusion ...
Vyondys 53
Vyondys 53 is used for Duchenne muscular dystrophy (DMD) in children and young adults with a ...
Exondys 51
Exondys 51 is used for Duchenne Muscular Dystrophy (DMD) in children and young adults with a ...
Golodirsen
Golodirsen is used to treat Duchenne muscular dystrophy (DMD) in children and young adults with a ...
Givinostat
Givinostat (Duvyzat) is used to treat Duchenne muscular dystrophy (DMD) to delay symptoms and ...
Eteplirsen
Eteplirsen is used for Duchenne Muscular Dystrophy (DMD) in children and young adults with a gene ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.